The incidence of malignant pleural mesothelioma is expected to increase globally. New treatment options for this malignancy are eagerly awaited to improve the survival and quality of life of patients. The present article highlights the results of recent advances in this field, analyzing data from several relevant trials. The heterogeneous tumor microenvironment and biology, together with the low mutational burden, pose a challenge for treating such tumors. So far, no single biomarker has been soundly correlated with targeted therapy development; thus, combination strategies are often required to improve outcomes. Locally applied vaccines, the expansion of genetically engineered immune cell populations such as T cells, the blockage of immune checkpoints that inhibit anti-tumorigenic responses and chemoimmunotherapy are among the most promising options expected to change the mesothelioma treatment landscape.
恶性胸膜间皮瘤的全球发病率预计将持续上升。目前亟需针对该恶性肿瘤的新治疗方案以改善患者生存期及生活质量。本文重点梳理该领域最新研究进展，通过对多项相关试验数据的分析指出：肿瘤微环境与生物学的异质性，加之较低的突变负荷，为此类肿瘤的治疗带来挑战。迄今为止，尚未发现单一生物标志物与靶向治疗发展存在明确关联，因此常需采用联合策略以改善疗效。局部应用疫苗、扩增基因工程免疫细胞群（如T细胞）、阻断抑制抗肿瘤反应的免疫检查点以及化学免疫疗法等，均有望改变间皮瘤的治疗格局。
The Current Treatment Landscape of Malignant Pleural Mesothelioma and Future Directions
肿瘤(癌症)患者之家